SCHEMBL21247337

SCHEMBL21247337

CC1(C)Cc2c(sc(NC(=O)c3ccccc3)c2C(=O)O)C(C)(C)C1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 1/20 0.68
▸ MAPT P10636 10/20 0.57
▸ ALDH1A1 P00352 8/20 0.57
▸ KMT2A Q03164 6/20 0.57
▸ MEN1 O00255 5/20 0.57
▸ SMN1; SMN2 Q16637 4/20 0.57
▸ RAB9A P51151 3/20 0.57
▸ NPC1 O15118 3/20 0.57
▸ KDM4E B2RXH2 2/20 0.57
▸ HPGD P15428 6/20 0.53
▸ LMNA P02545 3/20 0.53
▸ POLB P06746 1/20 0.53
▸ ESR2 Q92731 1/20 0.53
▸ CTDSP1 Q9GZU7 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ RAB7A P51149 5/20 0.53
▸ PLA2G1B P04054 2/20 0.48
▸ ATG4B Q9Y4P1 2/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21247234 0.90 PTPN1 (0.64) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21247200 0.85 PTPN1 (0.61) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21261123 0.84 PTPN1 (0.57) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21247155 0.83 PTPN1 (0.56) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21247159 0.83 PTPN1 (0.56) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21247208 0.83 PTPN1 (0.56) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21247297 0.83 PTPN1 (0.56) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21261108 0.83 PTPN1 (0.56) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21261018 0.82 PTPN1 (0.60) PTPN1MAPTALDH1A1KMT2AMEN1
SCHEMBL21260934 0.79 PTPN1 (0.73) PTPN1MAPTALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11492347-B2 Fused thiophene derivatives and their uses ENYO PHARMA (FR) 2022-11-08 — — US disclosed
EP-3749659-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO Pharma (FR) 2020-12-16 — — EP disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH PTPN1 1639/4885MAPT 2107/4885ALDH1A1 2143/4885
US-11492347-B2 Fused thiophene derivatives and their uses FTH1, SLC40A1, FECH PTPN1 1639/4885MAPT 2107/4885ALDH1A1 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback